References
- GOLD COPD [homepage on the Internet]Global Strategy for the Diagnosis Management and Prevention of COPD (updated 2015) GOLD, the Pocket Guide (updated 2015)2015 Available from: http://www.goldcopd.orgAccessed May 28, 2016
- Soler-CataluñaJJMartínez-GarcíaMARomán SánchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax20056092593116055622
- MiravitllesMAnzuetoALegnaniDPatient’s perception of exacerbations of COPD: the PERCEIVE studyRespir Med200710145346016938447
- CelliBVestboJJenkinsCRGender differences in mortality and clinical expressions of patients with COPD: the TORCH experienceAm J Respir Crit Care Med2010183331732220813884
- CurtisJLFreemanCMHoggJCThe immune-pathogenesis of chronic obstructive pulmonary disease: insights from recent researchProc Am Thorac Soc2007451252117878463
- DiamantZBootJDVirchowJCSumming up 100 years of asthmaRespir Med200710137838817258900
- Boswell-SmithVSpinaDPageCPPhosphodiesterase inhibitorsBr J Pharmacol2006147S252S25716402111
- VestboJPrescottELangePAssociation of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study GroupAm J Respir Crit Care Med1996153153015358630597
- RabeKFBatemanEDO’DonnellDWitteSBredenbrokerDBethkeTDRoflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trialLancet200536656357116099292
- CalverleyPMSanchez-TorilFMcIvorATeichmannPBredenbroekerDFabbriLMEffect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200717615416117463412
- CalverleyPMRabeKFGoehringUMM2-124 and M2-125 Study GroupsRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet200937468569419716960
- FabbriLMCalverleyPMIzquierdo-AlonsoJLRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long-acting bronchodilators: two randomised clinical trialsLancet200937469570319716961
- RennardSICalverleyPMGoehringUMBredenbrokerDMartinezFJReduction of exacerbations by the PDE4 inhibitor roflumilast the importance of defining different subsets of patients with COPDRespir Res2011121821272339
- LeeSDHuiDSMahayiddinAARoflumilast in Asian patients with COPD: a randomized placebo-controlled trialRespirology2011161249125721848706
- O’DonnellDEBredenbrökerDBroseMWebbKAPhysiological effects of roflumilast at rest and during exercise in COPDEur Respir J2012391104111221965226
- ZhengJYangJZhouXRoflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel group studyChest20141451445224135893
- MartinezFJCalverleyPMGoehringUMBroseMFabbriLMRabeKFEffect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trialLancet201538585786625684586
- HigginsJPThompsonSGQuantifying heterogeneity in a meta-analysisStat Med2002211539155812111919